

- Carbon disulfide, 2688t
- Carbonic anhydrase, 332e-3f, 332e-6-7
- Carbonic anhydrase II, 372e-24t
- Carbonic anhydrase inhibitors, 64e-3, 205, 246e-6t
- Carbon monoxide poisoning
- clinical features of, 248, 477e-5
 - complications of, 1782
 - epidemiology of, 477e-5
 - hypoxia in, 248
 - lactic acidosis in, 318
 - optic neuropathy in, 203
 - pathophysiology of, 477e-5-6, 639
 - polycythemia in, 400
 - treatment of, 477e-6, 1782
- Carbon tetrachloride, 2023, 2025t
- Carboplatin
- adverse effects of, 103e-9t, 103e-12, 103e-25, 1798, 1804
 - for carcinoma of unknown primary, 120e-4
 - for head and neck cancer, 505
 - for lung cancer, 518t, 520, 521t, 522
 - for melanoma, 499
 - for ovarian cancer, 593
 - as substitute for cisplatin, 622
 - for testicular cancer, 590, 591
 - for thymoma, 123e-2
- Carboxyhemoglobin, 400, 639
- Carboxypeptidase E, 415e-4, 415e-4t
- Carcinoembryonic antigen (CEA), 473t
- in cholangiocarcinoma, 552
 - in colorectal cancer, 76, 542t
 - reference values for, 2758t
- Carcinogen(s), 387, 476
- Carcinogenesis
- field, 477
 - initiation step in, 476
 - Knudson two-hit hypothesis of, 101e-2, 440
 - multistep nature of, 101e-1, 101e-1f, 440, 475
 - promotion, 476
 - radiation in, 103e-4
 - in skin, 387-388
- Carcinoid(s). *See* Gastrointestinal neuroendocrine tumors (GI-NETS)
- Carcinoid crisis, 565
- Carcinoid syndrome, 564
- atypical, 565
 - clinical features of, 96e-4, 269, 559t, 563t, 564-565
 - complications of, 565
 - diagnosis of, 356, 560f, 566
 - diarrhea in, 269, 855t
 - heart disease in, 565, 567, 1568
 - neuroendocrine tumors associated with, 558, 559t, 560f
 - pathobiology of, 559t, 560f, 565
 - pulmonic stenosis/regurgitation in, 1550
 - skin manifestations of, 356, 357, 360
 - treatment of, 272, 566-567, 566f
 - tumor locations in, 559t
- Carcinoma, 102e-1, 103e-1
- Carcinoma in situ, bladder, 575, 576
- Carcinoma of unknown primary, 120e-1, 503
- biology of, 120e-1
 - cytogenetics in, 120e-1
 - genetic considerations in, 120e-1
 - imaging in, 120e-1
 - immunohistochemical analysis in, 120e-2-3, 120e-2t
 - incidence of, 120e-1
 - molecular profiling in, 120e-2-3
 - pathology of, 120e-1-3, 120e-1t
 - prognosis of, 120e-3
 - treatment of, 120e-3-4, 120e-3f, 120e-4f
 - tumor markers in, 120e-1, 120e-2f
- carD* gene, 1106
- CARD15* gene mutations. *See* *NOD2* gene mutations
- Cardiac arrest, 1768
- clinical features of, 1768
 - death after successful resuscitation, 1768
 - definition of, 1764, 1765t
 - etiology of, 1764, 1765t
 - hypothermic, 478e-2
 - in-hospital, 1768, 1770
 - long-term management of survivors of, 1770
 - out-of-hospital, 1768
 - prevention of, 1767
 - primary, 1768
 - prodromal symptoms, 1768
 - prognosis of, 1768
 - progression to biologic death after, 1768
 - secondary, 1768
 - treatment of, 1768
 - advanced cardiac life support, 1769-1770
 - algorithm for, 1769f
 - automated external defibrillation, 1769
 - basic life support, 1768-1769
 - initial response, 1768
 - postresuscitation care, 1770
 - ventricular tachycardia and, 1491
- Cardiac arrhythmias. *See also specific arrhythmias*
- approach to the patient, 273e-4-5
 - bradyarrhythmias. *See* Bradyarrhythmias
 - diagnosis of, 273e-5
 - in heatstroke, 479e-2, 479e-3, 479e-4
 - in hyperkalemia, 310
 - hypertension and, 1615
 - in hypokalemia, 307
 - in hypomagnesemia, 2462
 - in hypothermia, 478e-3
 - in ischemic heart disease, 1580
 - mechanisms of, 273e-2, 273e-3t
 - abnormal impulse conduction, 273e-3t, 273e-4, 273e-4f
 - afterdepolarizations and trigger automaticity, 273e-2-3, 273e-3f, 273e-3t
 - alterations in impulse initiation, 273e-2-3, 273e-3t
 - in myocardial infarction, 1608-1610
 - physical examination in, 273e-5
 - in respiratory alkalosis, 323
 - respiratory sinus, 278e-1f
 - in sarcoidosis, 2208
 - syncope in. *See* Cardiac syncope
 - tachyarrhythmias. *See* Supraventricular tachyarrhythmias; Tachycardia
 - treatment of, 273e-5-7, 273e-6f, 273e-6t
 - warning arrhythmias, 1608
- Cardiac asthma, 1504
- Cardiac auscultation. *See* Heart murmurs; Heart sounds
- Cardiac biomarkers
- in myocardial infarction, 1594, 1596t, 1600-1601, 1601f
 - in VTE, 1633
- Cardiac cachexia, 1504
- Cardiac catheterization, 1460
- in aortic regurgitation, 1536
 - in aortic stenosis, 1531-1532
 - aortography during, 1464
 - in cardiogenic shock, 1760
 - coronary angiography during. *See* Coronary angiography
 - hemodynamic assessment in, 1461
 - cardiac output, 1462-1463
 - in constrictive/restrictive conditions, 1462, 1463t
 - intracardiac shunts, 1463
 - normal waveforms, 1462f
 - reference values for, 1461t
 - valve area, 1463
 - in valvular disease, 1462, 1462f
 - vascular resistance, 1463
 - indications for, 1460, 1460t
 - in mitral stenosis, 1541
 - postprocedure care, 1465
 - preprocedure management of, 1461
 - in pulmonary hypertension, 1657, 2161
 - racial/ethnic disparities in referral for, 16e-1
 - risks of, 1460-1461
 - in STEMI, 1605
 - technique of, 1461
 - vascular access for, 1461
 - ventriculography during, 1463-1464, 1464f
- Cardiac conduction system
- automaticity of, 273e-2-3
 - components of, 1451, 1451f
 - embryonic development of, 265e-12
- Cardiac contraction, 265e-5
- cardiac activation in, 265e-6-7, 265e-8f
 - cardiac ultrastructure and, 265e-5
 - contractile process in, 265e-5-6, 265e-5f, 265e-6f, 265e-7f
 - excitation-contraction coupling in, 265e-7f
 - sliding filament model for, 265e-5-6
- Cardiac glycosides, 473e-9t
- Cardiac imaging, 270e-1
- after myocardial infarction, 270e-19-20
 - in CAD evaluation. *See* Coronary artery disease (CAD), diagnosis of
 - in cardiac mass evaluation, 270e-23-24, 270e-23f, 270e-24f
 - in cardiac structure and function assessment, 270e-6-7
 - in chest pain evaluation. *See* Chest discomfort/pain, approach to the patient
 - in congenital heart disease, 270e-24-25, 270e-25f, 270e-26f. *See also specific defects*
 - contrast agents for, 270e-9
 - CT. *See* Computed tomography (CT), in cardiac disease
 - CT angiography. *See* Computed tomography (CT) angiography (CTA)
 - diagnostic accuracy of, 270e-9t
 - echocardiography. *See* Echocardiography
 - in infectious and inflammatory disease, 270e-24, 270e-24f, 270e-25f
 - MRI. *See* Cardiac magnetic resonance imaging (CMR)
 - in new-onset heart failure, 270e-21-22, 270e-21f, 270e-22f, 270e-27v
 - nuclear, 270e-2-4, 270e-2f. *See also* Myocardial perfusion imaging
 - in pericardial disease, 270e-22-23, 270e-22f, 271e-8f, 271e-8v
 - radiation exposure in, 270e-7-9
 - in valvular heart disease, 270e-15-16. *See also specific conditions*
- Cardiac index, 1748t
- Cardiac jelly, 265e-11
- Cardiac magnetic resonance imaging (CMR)
- after myocardial infarction, 270e-19-20, 270e-20f
 - in aortic regurgitation, 270e-18, 270e-18f, 270e-27v, 1536
 - in atrial myxoma, 289e-2f
 - in CAD evaluation, 270e-12-13, 270e-13f, 270e-26v
 - in cardiac amyloidosis, 270e-21, 270e-21f, 271e-6f
 - in cardiac masses, 270e-23-24, 270e-23f, 270e-24f
 - in chest pain evaluation, 102, 270e-15, 270e-15f, 270e-26v
 - in complete heart block, 271e-7f
 - in congenital heart disease, 270e-25, 270e-26f
 - in cor pulmonale, 1506
 - in hypertrophic cardiomyopathy, 270e-21, 270e-21f, 271e-7f, 271e-7v
 - in iron overload, 270e-21, 270e-27v
 - in left ventricular dysfunction evaluation, 270e-6, 270e-6v
 - in metastatic lung cancer, 271e-9f, 271e-9v
 - in mitral regurgitation, 270e-19
 - in myocardial infarction evaluation, 271e-4f, 271e-4v, 1601-1602
 - in myocarditis, 1559f
 - in patient with pacemaker/defibrillator, 270e-9
 - in pericarditis, 270e-23, 270e-23f, 270e-27v, 271e-8f, 1576f
 - principles of, 270e-4, 270e-6
 - pulse sequences for, 270e-6, 270e-6t
 - in right ventricular dysfunction, 270e-7, 270e-26v
 - stress testing with, 51e-8, 271e-3f, 271e-3v, 1585
 - in tetralogy of Fallot, 1527